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Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease characterized by the presence
of allergic granulomatosis and necrotizing vasculitis with eosinophilic infiltration. The etiology of EGPA is unknown.
Dendritic cells (DCs) are not only critical for the induction of primary immune responses; they may also be important
for the induction of immunological tolerance and the regulation of the type of T-cell-mediated immune response. To
investigate whether DC maturation is associated with EGPA disease status, we examined the relationship between the
maturation of DCs and the differentiation of regulatory T (Treg) cells in EGPA patients. We exposed the CD14
+
blood monocytes of 19 patients with EGPA in remission or relapse to stimulation with GM-CSF and IL-4 for 6 d and
lipopolysaccharide for 24 h to obtain mature CD83+ DCs and immature CD206+ DCs. Using immunohistochemistry, we
examined four patients for the presence of CD83+ and CD206+ DCs in the lung at the onset of EGPA.
Results: The percentage of CD83+ cells among DCs differentiated from CD14+ monocytes was lower for EGPA patients
in relapse than in remission. The percentage of CD83+ DCs was inversely correlated with the percentage of CD206+
DCs and was significantly correlated with the numbers of naturally occurring CD4+ regulatory Treg (nTreg; FOXP3
+CD4+)
cells and inducible Treg (iTreg; CD4+CD25+ T cells producing IL-10 or TGF-β) cells but not the number of eosinophils.
The percentage of CD206+ DCs was significantly inversely correlated with the percentages of nTreg and iTreg cells but
not the number of eosinophils. Immunohistochemistry revealed both CD206+ DCs and CD83+ DCs in alveoli and
interstitial spaces at the onset of EGPA.
Conclusion: The maturation of DCs from monocytes was related to disease activity in patients with EGPA. Increased
CD83+ DCs in EGPA patients may induce the differentiation of iTreg and nTreg cells, thereby suppressing inflammation
and disease activity.
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Eosinophilic granulomatosis with polyangiitis (EGPA; also
known as Churg–Strauss syndrome) is a rare disease char-
acterized by the presence of allergic granulomatosis and
necrotizing vasculitis. Development of the condition is pre-
ceded by peripheral blood eosinophilia and eosinophilic* Correspondence: n-tsurikisawa@sagamihara-hosp.gr.jp
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article, unless otherwise stated.tissue infiltration [1]. EGPA is classified as a vasculitis of ar-
teries that are small or medium in diameter, although such
vasculitis often is not apparent in the initial phases of the
disease [2]. Asthma is present in 96% to 100% of EGPA pa-
tients and is the cardinal feature of EGPA. Asthma may
precede systemic vasculitis by approximately 8 years and, in
some cases, by more than 30 years [1,3,4]. The precise eti-
ologies of EGPA and the asthmatic phase that precedes it,
as well as the role of genetic factors, remain unknown. In
our retrospective cohort study [5], we found that mosttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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asthma requiring treatment with systemic steroids or
mechanical ventilation, sinusitis, and a high percentage of
eosinophils in the peripheral blood. Chronic eosinophilic
pneumonia precedes systemic vasculitis in half of all pa-
tients with EGPA [4,6].
Regulatory T (Treg) cells play central roles in the main-
tenance of both immune homeostasis and peripheral tol-
erance. Naturally occurring CD4+ Treg (nTreg) cells that
constitutively express the forkhead box P (FOXP) 3 pro-
tein can also be identified because of their expression of
cytotoxic T-lymphocyte antigen-4 (CTLA-4), CD25, and
CD4 [7]. Peripheral differentiation of inducible Treg
(iTreg) cells form naïve CD4 T cells, which secrete IL-10,
requires an elevated level of serum TGF-β and increased
of IL-10 [8]. We previously confirmed that the mainten-
ance of Treg cell numbers in asthma patients with chronic
eosinophilic pneumonia may inhibit EGPA development
via the action of cytokines, such as IL-10 and TGF-β,
which are produced by CD4+CD25+ cells, and IL-2, which
is produced by CD4+CD25− T cells [9].
The mainstay of treatment for EGPA is systemic cor-
ticosteroid therapy. Additional treatment with im-
munosuppressive agents such as cyclophosphamide,
azathioprine, methotrexate, mycophenolate mofetil, ri-
tuximab, interferon-α, anti-IgE antibodies, anti-IL-5
antibodies, anti-TNF-α (infliximab, etanercept, adali-
mumab), plasma exchange, and intravenous immuno-
globulin therapy (IVIG) may be of benefit to some
patients [10]. The relapse rate is higher among patients
with EGPA than with microscopic polyangiitis (MPA);
some patients with EGPA experience frequent relapses
after initial clinical remission, whereas others fail to
achieve remission that lasts for an extended period
[11]. The mechanisms underlying the intractable form
of EGPA remain poorly understood.
In our previous studies, frequently relapsing EGPA pa-
tients, defined as patients who relapse at least once every
2 years after an initial period of remission, had decreased
numbers of Treg cell counts, CD19
+ B cells, and a lower
serum IgG concentration than those who did not experi-
ence frequent relapses. In patients with frequently relaps-
ing EGPA, decreases in Treg cell numbers and increased
percentages of activated B cells, such as CD80+, CD27+,
and CD95+ B cells, may induce apoptosis of B cells [12].
Treg cells are involved in the etiology and mechanisms of
EGPA, but their precise role is unknown, especially in
relation to antigen-presenting cells such as dendritic
cells (DCs).
DCs are widely recognized as the strongest antigen-
presenting cells and have the unique ability to induce a
primary immune response [13]. DCs can prevent or inhibit
T-cell-mediated effector responses through a variety of
mechanisms, ranging from the production of pleiotropicanti-inflammatory factors that exert broadly attenuating
effects to the induction of antigen-specific T cell responses
that result in anergy, deletion, or instruction of Treg cells
[14,15]. DCs bind to Treg cells in the presence of the
CD80/86 co-stimulatory molecule [14]. Immature DCs in-
duce IL-10–producing iTreg cells, reinforcing peripheral
tolerance [16].
Conventional DCs (cDCs, also known as myeloid DCs)
may play a pathophysiological role in the inflammation as-
sociated with antineutrophil cytoplasmic autoantibody
(ANCA)-associated vasculitis [17-19], granulomatosis
polyangiitis–Wegener granulomatosis [20], EGPA [21],
Kawasaki disease [22], and giant cell arteritis (GCA) [23].
Local increases in the number of activated myeloid DCs
probably impede the maintenance of tolerance and lead
to vascular autoimmune inflammation [24].
CD83 is a cell-surface marker characteristic of fully ma-
ture DCs [25-27]. In their function as antigen-presenting
cells, CD83-positive DCs induce T-cell-mediated immune
responses [26]. CD83-positive DCs have been associated
with activated EGPA [21] and multiple sclerosis [28]. Injec-
tions of soluble CD83 clearly reduce paralytic symptoms in
murine experimental autoimmune encephalomyelitis [29].
CD206 (macrophage mannose receptor, C type I) antigen is
upregulated in M2-type macrophages [30]. CD206-positive
antigen-presenting cells have high phagocytic capacity.
CD206 is expressed on immature DCs generated from
monocytes (MoDCs), whereas CD83 is expressed on ma-
ture MoDCs [31].
Although some reports suggest an association between
DCs and Treg cells [18,32,33], the details are still unclear.
To further explore whether DCs or Treg cells play a role
in the remission or relapse of EGPA, we examined the
relationship between the maturation of DCs and the dif-
ferentiation of Treg cells in EGPA patients.
Results
Clinical findings and treatment
Nineteen patients with EGPA were enrolled in the study
(Table 1). All patients had adult onset of the disease and
received systemic corticosteroids; 12 of the 19 patients
had immunosuppressants during initial treatment. Blood
was examined in 12 of the 19 patients at relapse and in
14 of the 19 patients at remission. The Birmingham Vas-
culitis Activity Score was higher in patients at relapse than
at remission. A higher percentage of patients used immu-
nosuppressants at relapse than at remission (Table 2). The
number of eosinophils in peripheral blood did not differ
between the two groups, but the percentage of FOXP3+
cells among CD4+ T cells (P < 0.01) and the percentages of
CD4+CD25+ T cells positive for IL-10 (P < 0.01), TGF-β
(P < 0.01), and IL-2 (P < 0.05; Mann–Whitney U test) were
lower in patients at relapse than in those at remission
(Table 2).
Table 1 Characteristics and therapy of patients with
EGPA (n = 19)
Age at the time of the study (years) 58.9 ± 16.9*
Male/Female 7/12
Atopic/nonatopic 6/13
Age at onset of EGPA (years) 52.6 ± 18.4
Duration of EGPA (years) 6.8 ± 3.6
At onset of EGPA
WBCs (/μL) 15561 ± 6238
Eosinophils (/μL) 8344 ± 5887
MPO-ANCA positive/negative 6/13
Clinical manifestations of EGPA
Number of organs involved 5.4 ± 1.9
Five-Factor Score 1996 1.1 ± 0.8





Multiple mononeuritis (yes/no) 19/0





Central nervous system (yes/no) 4/15
Arthralgia (yes/no) 9/10
Myalgia (yes/no) 7/10
BVAS at onset 35.1 ± 10.1
Initial treatment
Initial dose of PSL (mg) 44.2 ± 10.7
Immunosuppressant at initial treatment (yes/no) 12/7
CYC/AZA/CSA/MTX/RTX 10/1/1/0/0
WBC, white blood cell; MPO-ANCA, myeloperoxidase-specific antineutrophil
cytoplasmic autoantibody; MMT, the manual muscle test; BVAS, Birmingham
Vasculitis Activity Score; PSL, prednisolone; AZA, azathioprine; CSA, cyclosporin
A; CYC, cyclophosphamide; MTX, methotrexate; RTX, rituximab.
*Values are given as mean ± 1 standard deviation or as number.
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differentiated into DCs
The percentage of CD83+ cells among MoDCs was
28.4% ± 15.7% in healthy subjects compared with 64.6% ±
15.7% in EGPA patients at remission and 22.1% ± 15.3% in
patients with EGPA at relapse. The percentage of CD206+
cells among MoDCs was 16.65 ± 7.1% in healthy subjects,
10.3% ± 14.3% in patients whose EGPA was in remission,
and 80.0% ± 7.8% in patients with EGPA at relapse. The
percentage of CD83+ cells among MoDCs was lower in
EGPA patients in relapse than in remission (P < 0.01,Mann–Whitney U test; Figure 1A). In contrast, the per-
centage of CD206+ cells among MoDCs was higher in
EGPA patients during relapse than remission (P < 0.01,
Mann–Whitney U test; Figure 1B); technical difficulties
precluded the assessment of the percentage of CD206+
cells in 6 of the 19 patients. The percentage of CD83+
DCs was inversely correlated with the percentage of
CD206+ DCs (P < 0.01, Spearman’s rank correlation test;
Figure 2). We confirmed that the percentage of single-
labelled CD83+ DCs was significantly correlated with that
of CD83+ DCs with the CD11c+CD19− (P < 0.01, rs = 0.89)
or CD11c+CD56− (P < 0.01, rs = 0.99) expression patterns.
Correlation of CD83+ and CD206+ DCs and Treg cells
The percentage of CD83+ DCs was significantly (P <
0.01) correlated with the percentages of FOXP3+ CD4 T
cells (Figure 3A), CD4+CD25+ T cells producing IL-10
(Figure 3B), and CD4+CD25+ T cells producing TGF-β
(Figure 3C). However, the percentage of CD83+ DCs was
not correlated with the number of eosinophils in peripheral
blood (Figure 3D). In contrast, the percentage of CD206+
DCs was significantly (P < 0.01) inversely correlated with
the percentages of FOXP3+ CD4+ T cells (Figure 4A), CD4+
CD25+ T cells producing IL-10 (Figure 4B), and CD4+
CD25+ T cells producing TGF-β (Figure 4C). The percent-
age of CD206+ cells among DCs was not correlated with
the number of eosinophils in peripheral blood (Figure 4D).
We confirmed that CD83+ DCs induced from CD14+
monocytes produced IL-10 in patients with EGPA at remis-
sion (Figure 5). In the three patients of this study with
EGPA at remission, the percentage (mean ± SD) of CD83+
DCs that produced IL-10 was 0.76% ± 0.73%.
Immunochemistry of CD83+ and CD206+ DCs ex vivo and
in vivo
We used an anti-CD206 antibody to label immature
MoDCs obtained from patients with EGPA. Immature
CD206+ DCs had few dendrites and a rounded form
(Figure 6A). More CD206+ immature DCs were present in
patients with EGPA at onset than at remission (Figure 6
A,B). In contrast, mature DCs labeled with an anti-CD83
antibody had many dendrites (Figure 6D) and were more
frequent in patients with EGPA in remission than in those
at EGPA onset (Figure 6C,D).
We labeled CD206+ immature and CD83+ mature DCs
of five patients of 19 patients who had ground-glass opacity
or consolidation in the lungs. Eleven of 19 patients had
lung involvements by diagnostic imaging. Lung biopsy tis-
sue from a representative five patients with EGPA at onset
who had not been treated with systemic corticosteroids had
both CD206+ DCs (Figure 7A) and CD83+ DCs (Figure 7B)
in the alveoli and interalveolar spaces. CD83+ DCs also
were present in the respiratory bronchioles. However, we
saw few CD83+ or CD206+ DCs in lung tissue from EGPA
Table 2 Patient characteristics at assay
Relapse n = 12 Remission n = 14 P
Duration from onset of EGPA (months) 61.3 ± 100.7 75.1 ± 96.4 NS*
BVAS at relapse or remission 14.5 ± 9.5 0 ± 0 < 0.01*
Prednisolone dose at relapse or remission 10.4 ± 4.6 9.6 ± 7.6 NS*
Immunosuppressant use at relapse or remission (%) 75 35.7 <0.05
CYC/AZA/CSA/MTX/RTX 7/1/1/0/0 3/2/0/0/0 NS‡
No. of eosinophils in peripheral blood 350.8 ± 262.0 309.3 ± 273.2 NS*
FOXP3+ cells among CD4+ T cells (%) 0.5 ± 0.4 5.8 ± 2.1 < 0.01†
IL-10+ cells among CD4+CD25+ T cells (%) 0.3 ± 0.8 10.9 ± 11.4 < 0.01†
TGF-β+ among CD4+CD25+ T cells (%) 0.2 ± 0.7 7.4 ± 6.1 < 0.01†
IL-2+ among CD4+CD25− T cells (%) 9.9 ± 14.1 32.2 ± 25.3 < 0.05†
BVAS, Birmingham Vasculitis Activity Score; AZA, azathioprine; CSA, cyclosporin A; CYC, cyclophosphamide; MTX, methotrexate; RTX, rituximab; NS, not significant.
A P value of <0.05 was considered to be statistically significant.
*Two-way ANOVA using repeated-measures algorithm.
†Mann–Whitney U-test.
‡Chi-squared testing revealed no significant differences between the frequencies of the characteristics measured in the two groups.
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immunosuppressants, and IVIG (data not shown).
Discussion
Not only are DCs crucial for the induction of primary
immune responses, but these cells may also be import-
ant for the induction of immunological tolerance and
the regulation of the type of T-cell–mediated immune
response [34]. The cytokine Flt3 ligand and its receptor
Flt3required for the development of plasmacytoid DCs,
and cDCs [35]. Plasmacytoid DCs develop in the bone
marrow and accumulate mainly in the blood and lymph-
oid tissues and enter lymph nodes through the blood cir-
culation [36]. Like plasmacytoid DCs, pre-cDCs developFigure 1 Mature and immature DCs in EGPA patients during remissio
blood cells from patients with EGPA during remission or relapse, and cell-s
(A) Percentage of DCs positive for CD83 (mature DCs). (B) Percentage of ce
groups were evaluated by using the Mann–Whitney U test. †, P < 0.01.from a common DC progenitor in the bone marrow;
pre-cDCs differentiate into cDCs, which migrate through
the blood to lymphoid and non-lymphoid tissues [37].
Whereas plasmacytoid DCs differentiate into immuno-
genic DCs that can prime T cells against viral antigens
[38], cDCs have an enhanced ability to sense and respond
to tissue injury, capture environmental and cell-associated
antigens, process and present phagocytosed antigens to T
lymphocytes, and prime T cell responses [37].
CD83+ DCs have been reported to reflect disease activity
in inflammatory disease [21,28,29]. Here we have shown
in vivo that both mature CD83+ DCs and immature
CD206+ DCs can be present in the alveoli and interstitial
spaces of the lungs at the onset of EGPA. After we inducedn and relapse. DC cells were induced from monocytes in peripheral
urface markers were labeled by using immunocytochemistry.
lls positive for CD206 (immature DCs). Differences between patient
Figure 2 Inverse correlation between percentages of mature and
immature DCs. Correlation between the percentages of CD83-positive
DCs and CD206-positive DCs induced from monocytes in peripheral
blood cells in EGPA patients experiencing relapse (closed circles) and
remission (open circles). The correlation coefficient (rs) was obtained by
using the Spearman’s rank correlation test.
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found that MoDCs that expressed CD83+ were predomin-
ant in patients in remission, whereas MoDCs expressing
CD206+ predominated in samples from patients at relapse.
Many kinds of inflammatory cells, including eosinophils,
effector T cells, Treg cells, Th1 cells, Th2 cells, and Th17
cells, are present in the peripheral blood during the active
phase of EGPA [39,40]. We hypothesized that the inflam-
matory cells present in increased numbers during the ac-
tive phase might migrate into the alveoli and interstitial
spaces of the lungs.
In patients with EGPA, the number and percentage of
mature CD83+ DCs were inversely correlated with those
of immature CD206+ MoDCs. In addition, the percentage
of CD83+ DCs was higher in patients with EGPA in remis-
sion than in relapse and correlated with the percentage of
Treg cells. According to previous reports [18,33], CD83
+
DCs suppress the immune response, probably by inducing
Treg. Mature DCs expressing CD83
+ at remission, which
were present in higher numbers after treatment with corti-
costeroids, immunosuppressants, and IVIG, might induce
the differentiation of both iTreg cells and nTreg cells. In
contrast, we saw few CD83+ or CD206+ DCs in the lung
in vivo at remission after treatment with corticosteroids,
immunosuppressants, and IVIG, but this therapy did not
affect the number of eosinophils, which is already high in
patients with EGPA before the onset of vasculitis.
We previously reported that the percentage of CD4+ T
cells producing IL-17 and IL-22 (Th17 cells) is signifi-
cantly greater in patients with active EGPA than in healthycontrols or in patients with asthma, chronic eosinophilic
pneumonia, or inactive EGPA [40]. As stated earlier, eo-
sinophilia is characteristic of EGPA, and some reports sug-
gest that the IL-25 produced by eosinophils promotes
innate adaptive immunity by enhancing Th2 cytokine pro-
duction [41]. We have demonstrated that Th17 cells are
correlated with the number of CD4+ T cells that produce
IL-25 [42]. The number of Th17 cells is higher and that of
iTreg cells is lower in patients with active EGPA than in
those with inactive EGPA [40]. The mechanism of EGPA
is thought to involve the actions of Th2 cells, Treg cells,
and Th17 cells. This result may indicate again that mature
DCs that express CD83+ are associated with the differenti-
ation of Treg cells but with not the number of eosinophils.
Indoleamine 2,3-dioxygenase (IDO) can be induced in
many human cell types in vitro by stimulation with in-
terferons, lipopolysaccharide, tumor-necrosis factor-α
(TNF-α), Toll-like receptor (TLR) ligands, or FcεRI. IDO
is an interferon-inducible enzyme that suppresses adap-
tive T-cell immunity by catabolizing the essential amino
acid tryptophan in the cellular microenvironment [43].
IDO expression in monocytes from EGPA patients is
positively correlated with the percentage of CD4+CD25+
Treg cells producing IL-10 and inversely correlated with
the percentage of Th17 cells [42]. Therefore, EGPA relapse
may be linked to elevated levels of IL-25–producing CD4+
T cells, which promote Th2 inflammation and decrease
iTreg cell subpopulations, as does decreased IDO expres-
sion in monocytes. Therefore, the percentages of Th17
cells and of CD4+CD25+ Treg cells producing IL-10 both
reflect the disease activity of EGPA [42].
Together with co-stimulatory molecules such as CD80
and CD86, CD83 is strongly upregulated during inflam-
mation [44]. Ligation of CTLA-4 to CD80 or CD86 or
both may trigger the IDO pathway in DCs, in turn acti-
vating the transcription factor FOXP3 (which regulates
immune functioning) and inhibiting cytokine production
by DCs [45]. We demonstrated that patients with EGPA
who experience frequent relapses after initial clinical re-
mission have decreased Treg cell counts; increased per-
centages of B cells positive for CD80, CD27, or CD95;
lower CD19+ B cell counts; and lower serum IgG than do
those who maintain remission [12]. In contrast, other pa-
tients never achieve clinical remission [12]. These results
suggest that an interaction between Treg cells and B cells
via the overexpression of costimulatory molecules such as
CD80 is related to EGPA disease severity.
TLRs constitute a family of transmembrane proteins
that are expressed by various cell types, including antigen-
presenting cells. TLRs function to discriminate pathogens
and initiate inflammatory signaling pathways [46]. TLR4,
TLR5, TLR7, and TLR9 may play a role in vasculitis
[47,48]. DCs localized at the adventitia–media border of
medium-sized arteries in patients with GCA express a
Figure 3 Correlation of mature DCs with other immune cell types. Correlation between the percentage of CD83-positive DCs and the
percentages of FOXP3+ CD4+ T (nTreg) cells (A), IL-10
+ CD25+CD4+ T (iTreg) cells (B), and TGF-β+ CD25+CD4+ T (iTreg) cells (C) and the number of
eosinophils (D) in peripheral blood. Correlation coefficients (rs) were obtained by using Spearman’s rank correlation test. Closed circles, patients
experiencing relapse; open circles, patients in remission.
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T cells [49]. LPS-induced triggering of TLR4 activates
DCs, suggesting a key role for TLR4 in the induction of
the inflammatory processes in GCA [50]. These researches
may help to elucidate the etiology of vasculitis.
The remission rate after initial treatment is reported to
be 81% to 91% in EGPA patients, compared with 30% to
93% in patients with GPA and 75% to 89% in those with
MPA [11]. However, the relapse rate during the first 2 years
after diagnosis is higher in EGPA patients (35%) than in
MPA patients (8%) [11]. The relapse rate at 5 years or
more after disease onset is greater than 60% in patientswith EGPA, compared with 20% in MPA patients [51].
Why the relapse rate of EGPA is so high is unknown, but
vasculitis relapse might occur when unknown events in
the peripheral blood or blood vessels lead to an interaction
between DCs and Treg cells, thereby causing an immune
response.Conclusion
We conclude that CD83+ DCs are related to EGPA dis-
ease activity. Specifically, an increase in the number of
CD83+ DCs generated from monocytes may induce the
Figure 4 Correlation of immature DCs with other immune cell types. Correlation between percentage of CD206+ DCs and the percentages
of FOXP3+ CD4+ T cells (A), IL-10+ CD25+CD4+ T cells (B), and TGF-β+ CD25+CD4+ T cells (C) and the number of eosinophils (D) in peripheral
blood. Correlation coefficients (rs) were obtained by using Spearman’s rank correlation test. Closed circles, patients experiencing relapse; open
circles, patients experiencing remission.
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lead to remission in patients with EGPA.
Methods
Patients
Between March and October 2006, we recruited 19 pa-
tients with EGPA and 7 healthy subjects at the Clinical
Research Center for Allergy and Rheumatology (National
Hospital Organization, Sagamihara, Kanagawa, Japan).
The Ethics Committee of our hospital approved the study,
and written informed consent was obtained from each
subject. EGPA was defined in all patients according to the
classification criteria of the American College of Rheuma-
tology [52]. A patient was considered to be in remissionwhen the disease was inactive and when no clinical sign or
symptom of active vasculitis had been evident for 6 months
or more. A relapse was defined as the presence of active
disease combined with the recurrence, after initial remis-
sion, of vasculitis symptoms (with or without an increase in
the percentage of eosinophils among white blood cells). Pa-
tients who relapsed required resumption of immunosup-
pressive therapy or increased doses of immunosuppressant.
Disease activity was assessed at first diagnosis and at
first relapse by using the Birmingham Vasculitis Activity
Score [53]. This scheme evaluates symptoms and signs
within 9 categories (systemic; cutaneous; mucous mem-
branes and eyes; ear, nose, and throat; chest; heart and
vessels; gastrointestinal tract; renal system; and nervous
Figure 5 CD83+ DC producing IL-10. CD83-positive DCs treated with a control (A) or an anti-IL-10 antibody (B) after CD14+ monocytes from
patients with EGPA in remission were incubated with GM-CSF and IL-4, stimulated with lipopolysaccharide, and analyzed by flow cytometry.
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category is 7; the maximal score is thus 63. In addition,
blood samples obtained from patients with EGPA during
relapse (in the active disease state) or remission (when
the disease was inactive) were evaluated.
Multiple mononeuritis, a measure of motor nerve dys-
function, was evaluated by using the manual muscle test;
responses were scored from 0 to 5 on the Medical Research
Council scale. Sensory nerve dysfunction was evaluated by
clinical examination. Lung involvement was consideredFigure 6 Mature and immature DCs at onset and remission. DCs induc
onset (A, C) or remission (B, D) were stained for CD83 (A, B) or CD206 (C,present when any of the following was present: consolida-
tion, ground-glass opacity, nodules within such opacity,
interlobular septal thickening, bronchial wall thickening,
lymph node enlargement, pleural effusion evident upon
high-resolution computed tomography, or eosinophilic in-
filtration detected by lung biopsy. The heart was considered
to be involved when any of the following was evident: chest
pain, chest discomfort, back pain, palpitations, abnormal
signs on cardiac echocardiography, Holter electrocardio-
graphic abnormalities, elevated B-type natriuretic peptideed from monocytes in peripheral blood of patients with EGPA at
D). Magnification, ×200.
Figure 7 DCs in a lung biopsy. Immunohistochemistry for CD206 (A) and CD83 (B) was performed on lung tissue from a representative patient
with EGPA at onset. Magnification × 100.
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aging abnormalities [54]. Gastrointestinal involvement was
indicated by the presence of symptoms of epigastralgia, ab-
dominal pain, diarrhea, constipation, or positive endoscopic
signs, combined with confirmation of eosinophil infiltration
by biopsy. Skin involvement was defined as the presence of
purpura, erythema, livedo, an ulcer, or acrocyanosis when a
nodule, accompanied by eosinophilic infiltration, was de-
tected by biopsy. Central nervous system involvement was
defined as the presence of headache, visual disorder, abnor-
mal visual sensation, cerebral infarction, bleeding, or cranial
nerve dysfunction. Renal involvement was defined as the
presence of eosinophils in urine, glomerular nephritis,
nephrosis, renal dysfunction (i.e., the creatinine level was el-
evated more than 20% over the baseline value), or protein-
uria (>0.5 g per day). Disease severity in all EGPA patients
was evaluated by using the Five-Factor Score 1996 [55] or
Five-Factor Score 2009 [56]. The organs compromised by
asthma and sinusitis were not included in the total count of
involved organs.
The eosinophils in whole blood and Treg cells in per-
ipheral blood (FOXP3+ cells among CD4+ T cells, or IL-
10-producing cells among CD4+/CD25+ T cells, or
TGF-β-producing cells among CD4+/CD25+ T cells)
were counted in all patients at relapse or during remission.
Immunological analysis
Differentiation of DCs expressing CD83+ or CD206+ from
CD14+ blood monocytes
Mononuclear cells were isolated by using Ficoll–Paque
(Lymphocyte Separation Media, catalog no. CPL-50494-
5, Cosmo Bio. Co. Ltd., Tokyo, Japan) density-gradient
centrifugation of heparinized blood obtained from EGPA
patients [27]. To this end, white blood cells treated with
4.5% dextran to remove red blood cells were washed
twice with PBS and layered onto Lymphocyte Separation
Media. After centrifugation at 800 × g for 20 minutes,the mononuclear-cell-enriched population was har-
vested, and these cells were washed twice with PBS after
centrifugation at 300 × g for 10 minutes. Peripheral
blood mononuclear cells (PBMCs) were resuspended
(1 × 106 cells/mL) in RPMI 1640 medium (GIBCO/BRL,
Grand Island, NY, USA) containing 10% (vol/vol) fetal
calf serum, 10 mM glutamine, and penicillin–strepto-
mycin. The resulting T-cell-depleted mononuclear cells
were cultured at 37°C for 3 h in 100-mm tissue culture
plates and washed twice with PBS to remove residual
debris from the plates. The purified plastic-adherent
monocyte population was confirmed to be more than
97% CD14+ monocytes.
CD14+ monocytes were cultured in 6-well tissue cul-
ture plates (1 × 106 cells/mL) in medium containing cy-
tokines (GM-CSF [50 ng/mL] and IL-4 [10 ng/mL])
purchased from BioLegend (Cosmo Bio. Co. Ltd.) or
R&D Systems (Tokyo, Japan). The cultures were fed with
fresh medium and cytokines every 2 d, and cell differen-
tiation was monitored by light microscopy as described
[27]. After treatment with GM-CSF and IL-4 for 6 d,
CD14+ monocytes were stimulated by exposure to lipo-
polysaccharide for 24 h by fluorescence-based cell sort-
ing as described [57]. The collected cells were placed on
silanized slides and frozen at −80°C. Sections were pre-
incubated with PBS containing 5% (w/v) bovine serum
albumin (BSA; Sigma-Aldrich) for 30 min, followed by
incubation with mouse anti-CD83 antibody (BioLegend,
Cosmo Bio Co. Ltd.) or mouse anti-CD206 antibody (BD
Biosciences, Rikaken Co. Ltd., Tokyo, Japan) for 60 min
[57,58]. The slides were developed by incubation with
100 μL of DAB and then lightly counterstained with
Mayer’s hematoxylin. The percentage of CD83+ or CD206+
cells among CD14+ monocytes stimulated with GM-CSF,
IL-4, and lipopolysaccharide was evaluated by using image
analysis software (Image Pro Plus 6.0, Media Cybernetics,
Bethesda, MD, USA).
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pressing CD11+, CD19−, or CD56− expression patterns from
CD14+ blood monocytes and the percentage of CD83+
DCs producing IL-10 were analyzed by flow cytometry.
Transbronchial lung biopsy
Bronchoscopy was performed in accordance with inter-
national guidelines [59]. After premedication with 4%
lidocaine by nebulizer and spray, all patients were anaes-
thetized intravenously with 3 mg midazolam hydrochloride.
A bronchoscope (Olympus BF-1 T240, Olympus Optical
Co., Tokyo, Japan) was inserted through the mouth and
pharynx, and the trachea and bronchi were anaesthetized
with 4% lidocaine administered during maintenance with
oxygen at 3 L/min via nasal cannula. Four patients who
had ground-glass opacity or consolidation on computed
tomography underwent lung biopsies at onset of EGPA.
Two or three specimens per patient were taken from lungs
with ground-glass opacity or consolidation on computed
tomography images.
Immunohistochemistry of the lung
Lung specimens were embedded in Optimal Cutting
Temperature compound (OCT, Bayer-Pharma, Zurich,
Switzerland) and frozen at −80°C. We immunostained 8-
μm sections on silanized slides in an Autostainer slide
processor (DakoCytomation, Kyoto, Japan) as described
[60]. Briefly, the sections were incubated with 10% for-
malin for 15 min, and then washed with PBS twice for
5 min each wash. Endogenous peroxidase activity was
blocked by incubation with peroxidase-blocking solution
(Dako A/S Ltd, Glostrup, Denmark) for 10 min at room
temperature. The slides then were washed with PBS twice
for 5 min each. Antigen retrieval for all antibody treatments
consisted of autoclave treatment of sections for 30 min in
either Epitope Retrieval Solution (DakoCytomation) or Tar-
get Retrieval Solution (pH 6.0, DakoCytomation). The slides
were incubated with primary antibodies overnight at 4°C by
using Envision kits (DakoCytomation), followed by
30 min with horseradish peroxidase–labeled complex
conjugated with secondary antibody and 30 min with sub-
strate–chromogen (DAB) solution (DakoCytomation).
The sections were lightly counterstained with Mayer’s
hematoxylin. Mouse monoclonal antibodies against CD83
(BioLegend, Cosmo Bio Co. Ltd.) and CD206 (BD Biosci-
ences, Rikaken Co. Ltd.) were used. Signals corresponding
to CD83+ or CD206+ cells were developed by incubation in
100 μL of DAB. Staining of CD83 indicated a mature DC,
and staining of CD206 indicated an immature DC [60,61].
Enumeration of FOXP3+ cells among CD4+ T cells
Peripheral blood cells were assayed as described by
Abdulahad et al. [62] to determine the percentages of
CD25+ and FOXP3+ cells among CD4+ T cells. FOXP3+cells among CD4+ T cells (termed FOXP3+ CD4+ T cells)
were identified by incubating whole-blood lymphocytes
with phycoerythrin-conjugated anti-FOXP3 antibody
(BD Biosciences) after cell permeabilization with 4% (v/v)
formaldehyde and 0.1% (w/v) saponin. Expression of sur-
face and intracellular markers of CD4+ T cells (identified
by an anti-CD4 antibody from BioLegend) was analyzed by
flow cytometry (FACSCalibur, Nippon Becton Dickinson,
Tokyo, Japan).
Induction of cytokine expression and staining of
intracellular cytokines to identify iTreg cells
To induce cytokine expression and accumulation, periph-
eral blood mononuclear cells (PBMCs) were stimulated for
4 h at 37°C with 10 μg/mL brefeldin A in the presence or
absence of 20 ng/mL phorbol myristate acetate and 1 μg/
mL ionomycin [63]. We removed cells that died after such
stimulation. Separated PBMCs were stimulated with 50 ng/
mL phorbol myristate acetate and 1 μg/mL ionomycin for
4 h at 37°C, and 1 × 106 PBMCs were suspended in RPMI
1640 medium supplemented with 1 mL of 10% FCS. The
percentage of dead cells among PBMCs treated with phor-
bol myristate acetate and ionomycin was calculated under a
microscope after addition of 40 μL trypan blue diluent. The
control was whole-blood cells diluted to the same extent in
FCS-free RPMI 1640 before the addition of trypan blue.
The percentage of dead cells was 7.0% ± 6.7%. Dead cells
could not be distinguished from live cell by flow cytometry,
but the inclusion of the dead cells did not change the statis-
tical significance of the percentage of positive cells produ-
cing cytokines. Surface-stained whole-blood lymphocyte
samples were suspended in 0.5 mL cold 4% (v/v) parafor-
maldehyde (used as a fixative) and incubated at room
temperature for 10 min. Next, the cells were washed twice
with PBS and centrifuged at 200 × g for 7 min. Each pellet
thus obtained was suspended in 2 mL serum amyloid P
buffer (0.1% [w/v] saponin, 0.05% [w/v] NaN3 in Hanks’s
balanced salt solution). Each cell suspension was again cen-
trifuged at 200 × g for 7 min, and each cell pellet was sus-
pended in 0.1 mL serum amyloid P buffer. Cell suspensions
were diluted with PBS and divided into aliquots of 106 cells
in 20 μL. Phycoerythrin-conjugated anti-human IL-10 and
TGF-β were purchased from BioLegend (San Diego, CA)
and added to each tube. All tubes were vortexed and incu-
bated for 35 min at room temperature in the dark. The per-
centage of cells generating cytokines was measured by flow
cytometry, and the data were analyzed by using CELLQuest
software (Nippon Becton Dickinson).
Human iTreg cells were defined as CD4
+/CD25+ T cells
that produced either IL-10 as the dominant cytokine (these
cells were termed IL10+ CD4+ CD25+ T cells) or that pre-
dominantly produced TGF-β [7]. Human nTreg cells were
defined as FOXP3+ CD4+ T cells and were identified as de-
scribed previously [64,65].
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All values are expressed as mean ± 1 SD unless otherwise
specified. Statistical comparisons among groups were
achieved by using two-way analysis of variance with a
repeated-measures algorithm followed by post-hoc com-
parisons using the Newman–Keuls test. Correlation coeffi-
cients were obtained by using Spearman’s rank correlation
test. A P value < 0.05 was considered statistically signifi-
cant. Statistical analysis was performed by using SPSS for
Windows, version 20 (SPSS Inc., Chicago, IL, USA).
Abbreviation
ANCA: Antineutrophil cytoplasmic autoantibody; CTLA-4: Cytotoxic
T-lymphocyte antigen-4; cDC: Conventional DC; DC: Dendritic cell; MoDC: DC
generated from monocytes; EGPA: Eosinophilic granulomatosis with
polyangiitis; FOXP3: Forkhead box P; GPA: Granulomatosis polyangiitis;
IDO: Indoleamine 2, 3-dioxygenase; IVIG: Intravenous immunoglobulin;
MPA: Microscopic polyangiitis; PBMC: Peripheral blood mononuclear cell;
SLE: Systemic lupus erythematosus; TLR: Toll-like receptor; Treg cells: Regulatory
T cells.
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